External validation of a risk stratification model to assist shared decision making for patients starting renal replacement therapy by PEETERS, PATRICK et al.
RESEARCH ARTICLE Open Access
External Validation of a risk stratification
model to assist shared decision making for
patients starting renal replacement therapy
Patrick Peeters1, Wim Van Biesen1*, Nic Veys1, Wim Lemahieu2, Bart De Moor3 and Johan De Meester4
Abstract
Background: Shared decision making is nowadays acknowledged as an essential step when deciding on starting
renal replacement therapy. Valid risk stratification of prognosis is, besides discussing quality of life, crucial in this
regard. We intended to validate a recently published risk stratification model in a large cohort of incident patients
starting renal replacement therapy in Flanders.
Methods: During 3 years (2001–2003), the data set collected for the Nederlandstalige Belgische Vereniging voor
Nefrologie (NBVN) registry was expanded with parameters of comorbidity. For all incident patients, the abbreviated
REIN score(aREIN), being the REIN score without the parameter “mobility”, was calculated, and prognostication of
mortality at 3, 6 and 12 month after start of renal replacement therapy (RRT) was evaluated.
Results: Three thousand four hundred seventy-two patients started RRT in Flanders during the observation
period (mean age 67.6 ± 14.3, 56.7 % men, 33.6 % diabetes). The mean aREIN score was 4.1 ± 2.8, and 56.8, 23.1,
12.6 and 7.4 % of patients had a score of ≤4, 5–6, 7–8 or ≥9 respectively. Mortality at 3, 6 and 12 months was
8.6, 14.1 and 19.6 % in the overall and 13.2, 21.5 and 31.9 % in the group with age >75 respectively. In RoC
analysis, the aREIN score had an AUC of 0.74 for prediction of survival at 3, 6 and 12 months. There was an
incremental increase in mortality with the aREIN score from 5.6 to 45.8 % mortality at 6 months for those with
a score ≤4 or ≥9 respectively.
Conclusion: The aREIN score is a useful tool to predict short term prognosis of patients starting renal
replacement therapy as based on comorbidity and age, and delivers meaningful discrimination between low
and high risk populations. As such, it can be a useful instrument to be incorporated in shared decision making
on whether or not start of dialysis is worthwhile.
Background
Worldwide, age at inception of renal replacement therapy
is increasing. In Europe, the median age at start of RRT
has increased from 64 to 73 years over the last decade [1].
Whereas start of renal replacement therapy can be lifesav-
ing, it is associated with a high short term mortality and a
substantial decrease in quality of life for some patients
[2, 3]. In this setting, there is an increasing interest for
the concept of conservative care [4–6], as it is accepted
that for some patients the benefits of starting renal
replacement therapy do not outweigh the drawbacks.
Existing literature indicates that mere age on itself is
insufficient to prognosticate outcome after start of RRT,
and that rather presence of comorbidities should be
taken into account [7–9].
Studies indicate that physicians tend to be overly
optimistic on the prognosis of their patients [10]. Such a
failure to recognise a poor prognosis might lead to
perseveration of therapy and overemphasis of cure
rather than care [5, 11] and deprive patients from
achieving a good and serene death [4].
In order to discuss the option of conservative care
with patients, there is a need for risk stratification
models that can more objectively quantify prognosis.
Such models should be valid from the statistical point of
view, not only within the test population, but also in
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other external populations. Recently, a prognostic model
was developed for 5 year mortality versus need for RRT
in patients with CKD [12]. This model can be useful for
longer term planning of patients with CKD, but is not
intended to predict survival in patients with CKD stage
5, and cannot assist in decision making on whether to
start RRT or opt for conservative care.
Observational studies consistently demonstrate that as
comorbidity adds up, the survival advantage of starting
renal replacement goes down, and survival between
patients started on RRT and those with conservative care
become similar [9, 13, 14]. In this regard, risk stratifica-
tion models based on survival of patients who have actu-
ally started RRT can provide valid information in the
decision making of whether or not starting RRT is
warranted. Recently, such a model was published, based
on data from the Renal Epidemiology Information
Network (REIN) registry in France [15].
We intended to check the validity of this model in a large
registry cohort of patients starting RRT in the Flanders
region of Belgium, coordinated by the Nederlandstalige
Vereniging voor Nefrologie.
Methods
Patients
The registry of the NBVN is a voluntary database which
covers 100 % of all patients starting renal replacement
therapy in Flanders, Belgium. As in the REIN database,
patients with acute kidney injury are excluded.
The registry captures a basic set of baseline data through
a web based system consisting of the following items : date
of birth, gender, city/zip code, primary renal disease, date of
first contact at the nephrology department, weight, length,
serum creatinine at start of RRT, change of RTT modality
(type and date), and mortality (cause and date).
Between 1/1/2001 until 31/12/2003, a more expanded
set of data of comorbidities was collected at baseline,
one and two years, with the intention to allow prognos-
tic modelling. Baseline information at dialysis initiation
included age, gender, eGFR based on creatinine and the
MDRD formula, body mass index (BMI), serum albumin
the month preceding dialysis start, diabetes (type 1 or 2),
congestive heart failure (New York Heart Association
stages I to IV), ischaemic heart disease (including history
of myocardial infarction, coronary vascular disease,
coronary artery bypass surgery, angioplasty or abnormal
angiography), peripheral vascular disease (Leriche cla-
ssification stages I to IV), cerebrovascular disease,
arrhythmia, chronic obstructive pulmonary disease
(COPD), malignancy, liver cirrhosis, mental disorders
(defined to include dementia and psychosis), initial
dialysis modality, and late referral (defined as starting
dialysis less than 3 months after first contact with the
nephrology department.
Patient data were entered by the individual centres
and are validated on an ongoing basis by the registry
data manager.
Analysis
For each patient, the abbreviated REIN (aREIN) score
was calculated based on the baseline comorbidity data
as depicted in the original paper [15]. As the NBVN
registry does not capture data on mobility, this item
was omitted from the REIN score, and therefore, we
designated this as the “abbreviated REIN score”
(aREIN score) (Table 1).
Demographic data of patients were represented as
mean ± standard deviation for continuous variables or n
Table 1 Parameters of the abbreviated REIN score
Risk factors Points
Gender
Male 1
Female 0
Age (years)
[75–80] 0
[80–85] 0
[85–90] 2
> = 90 3
Congestive heart failure
No 0
Stage I-II 2
Stage III-IV 4
Peripheral vascular disease
No or stage I-II 0
Stage III-IV 1
Arrhythmia
No 0
Yes 1
Cancer
No 0
Yes 2
Severe behavioural disorder
No 0
Yes 2
Serum Albumin (g/l)
<25 5
[25–30] 3
[30–35] 2
≥35 0
The abbreviated REIN score is the REIN score without the “mobility topic”. In
the original REIN score, patients get 0 points if they walk without help, 4
points if they need assistance for transfer and 9 points if they are totally
dependent for transfer
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Table 2 Demographic data of included patients, stratified according to the abbreviated REIN score
Abbreviated REIN score ≤4 n = 1523 5–6 n = 619 7–8 n = 338 ≥9 n = 199 p-value
Screa at start (mg/dl) 7.2 ± 3.1 6.3 ± 2.7 6.4 ± 4.5 5.9 ± 3.1 <0.001
Weight (kg) 71.6 ± 15.7 71.6 ± 14.5 69.8 ± 14.5 69.3 ± 16.1 0.18
Height (cm) 166.5 ± 9.3 166.0 ± 8.1 168.5 ± 9.3 166.6 ± 9.1 0.21
Age at start (years) 64.0 ± 15.2 71.7 ± 11.0 77.5 ± 10.8 67.8 ± 14.3 <0.001
Female (%) 48.1 38.6 34.6 32.7 <0.001
Heart Failure Stage 0–1 70.7 34.4 16.9 8.5 <0.001
Stage 2 13.3 16.2 19.5 9.5
Stage 3 13.4 23.7 34.0 62.3
Stage 4 2.1 19.7 12.7 17.6
Angina Pectoris None 86.6 66.2 61.2 54.3 <0.001
Grade 1 7.4 14.1 16.0 16.1
Grade 2 4.1 9.9 9.5 8.0
Grade 3 1.4 6.9 10.1 14.6
Peripheral Vascular Disease <0.001
None 87.2 71.9 70.4 61.3
Claudicatio 8.1 15.2 15.7 17.6
Resting ischemia 1.4 3.6 3.8 7.0
Necrosis/amputation 3.2 9.4 10.1 14.1
COPD None 83.2 71.1 66.0 59.8 <0.001
Mild 9.8 17.4 19.5 18.1
Moderate 5.6 8.6 9.8 14.1
Severe 1.4 2.9 4.7 8.0
Myocardial Infarction 11 25.5 27.8 33.2 <0.001
Percutaneous Coronary Intervention 13 22.6 25.7 25.6 <0.001
Arrhythmia 6.4 18.4 28.7 44.2 <0.001
Diabetes 30.2 39.7 37.3 34.7 <0.001
Diabetic nephropathy 23 26.8 24.0 23.6 0.3
CerebroVascular Disease 8.7 8.7 13.7 15.0 <0.001
Dementia 0.7 2.4 7.4 8.5 <0.001
Liver disease 4.7 4.2 4.0 6.5 <0.001
Left ventricular Hypertrophy 49.5 51.5 51.2 54.8 0.6
Cancer 8.5 19.1 29.9 34.7 0.2
Nutritional status Normal 92 75.4 60.9 49.2 <0.001
Malnutrition 7.4 20.2 31.7 37.7
Severe malnutrition 0.6 4.4 13.1 13.1
Albumin (g/l) <25 0 18.3 27.2 45.2 <0.001
25–30 5.6 18.3 27.5 31.2
30–35 19.2 33.4 30.5 22.1
35–40 49.6 22.0 9.8 1.0
>40 25.6 8.1 5.0 0.5
C-reactive protein (mg/L) <15 73.3 54.1 44.1 40.7 <0.001
15–60 20.1 29.4 35.2 33.7
>60 6.6 16.5 20.7 25.6
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out of N (n/N) and percentages for categorical variables.
Between group comparisons were done with One Way
Analysis of Variance and post hoc testing with Least
Square Difference for continuous variables, or Chi-square
analysis for categorical variables.
Mortality rates at 3, 6 and 12 months were calculated,
and this for four different severity stages of the aREIN
score (low risk:≤4; moderate low risk: 5–6; moderate high
risk: 7–8; and high risk: ≥9 points). Those four groups
were selected as they represented a reasonable division of
our cohort and resulted in subgroups with comparable
mortality risk (see Additional file 1: Table S1).
Areas under the curve (AUC) were calculated for
prediction of 3, 6 and 12 months survival based on the
aREIN score.
Cox proportional hazards analysis was used to
model survival in the different severity stages of the
aREIN score.
All statistical analysis were performed in SPSS®version 22.
Results
During the observation period, 3472 patients started renal
replacement therapy. The demographic data of these
patients are depicted in Table 2 according to their aREIN
stage. For 793 patients (22.8 %) information on one
parameter of the REIN score was missing, making aREIN
score calculation impossible, leaving 2679 patients avail-
able for analysis. There was no difference in gender or age
between those with versus without missing data.
More than half (56.4 %) and almost three quarters
(70.3 %) of those older than 85 and 90 years of age re-
spectively at start of dialysis had an aREIN stage of 3 or 4.
We registered 276 (8.6 %), 453 (14.1 %) and 681
(19.6 %) deaths at 3, 6 and 12 months respectively.
Patients who died during the first 3 months were older
(74.3 ± 9.9 vs 67.0 ± 14.5 years, p < 0.001), had a higher
aREIN score at start (6.4 ± 2.7 vs 3.9 ± 2.7, p < 0.001),
and a lower serum creatinine (6.1 ± 3.8 vs 6.7 ± 3.1 mg/dl,
p < 0.01) and body weight (69.4 ± 15.5 vs 71.7 ± 15.7 kg,
p = 0.03) as compared to those who survived (Table 3).
Similar results were found for mortality at 6 and
12 months (results not shown).
Mortality at 3, 6 and 12 months according to 4 stages
of aREIN score is graphically presented in Fig. 1, show-
ing a good discrimination in mortality risk between the
different aREIN stages. The results for the separate
scores are presented in Additional file 1: Table S1.
Relative risk of death increased with each increasing
aREIN stage with a factor 1.80 (95 % CI: 1.67–1.92), 1.78
(95 % CI: 1.64–1.96) and 1.80 (95 % CI: 1.61–1.99) at 3,
6 and 12 months respectively.
Figure 2 presents these survival data in the different
aREIN stages in a format that facilitates shared decision
making with patients.
Area under the curves for 3, 6 and 12 months mortality
are 0.74 (95 % CI: 0.70–0.77), 0.74 (95%CI: 0.71–0.76) and
0.74 (95 % CI: 0.72–0.76).
Long term survival according to different stages of the
aREIN score is depicted in Fig. 3, confirming that also
longer term mortality risk goes up with aREIN stage.
Discussion
This paper provides an external validation for a recently
proposed risk stratification score for short term mortal-
ity in patients starting with renal replacement therapy
[15]. In the NBVN registry, 3 month mortality risk
ranged from 3 % in the lowest risk group to 24.6 % in
the highest risk group. The score also performed well in
discriminating risk at 6 and 12 months. In the highest
risk stage, mortality at one year was higher than 50 %,
whereas in the lowest risk stage, this was less than 10 %.
With each increase in the aREIN stage, the relative risk
for death at 3, 6 or 12 month increased with a factor 1.8.
The aREIN score is based on easily available items and
can be calculated by hand during outpatient con-
sultation. Items included in the score are all well-
acknowledged risk factors that are generally registered in
the patient file under one format or another, but are
rarely considered together to construct a global picture
of the patient. Therefore, the calculation of the risk
stratification score can help to increase a more holistic
awareness on the prognostic risk of a patient and to
identify patients at risk for a dismal outcome. The visual
representation of the risk of mortality after start of RRT
as depicted in Fig. 2 can help in the shared decision
making on whether to start renal replacement therapy
or to opt for conservative care.
Over the last decade, the age and comorbidity of
patients starting renal replacement therapy has steadily
increased [1]. In Flanders for example, the median age at
start increased from 67.7 years in 1997 to 74.7 years in
2013. Over this period, the percentage of patients >75 years
of age increased from 22.8 to 36.7 %, while over the
same time period, comorbidity of patients starting
Table 2 Demographic data of included patients, stratified according to the abbreviated REIN score (Continued)
Renal Replacement Therapy <0.001
Hospital HD 77.7 80.9 85.8 88.4
Satellite HD 9.5 12.1 6.5 6.5
PD 12.8 6.9 7.7 4.5
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RTT went up [16]. At the same time, withdrawal of
dialysis as reason for death increased from 12.9 to
20.8 % [16], and many patients indicate they regret
having started RRT [17].
As reported in many other studies, also in the current
cohort, short term survival is abysmal especially in the
older age group (>85). Several authors have indicated
that not age per se, but rather underlying comorbidity,
might be a predictor of poor outcome, and that outcome
can be good even in the elderly, provided there are no
other comorbidities present [9, 13]. Indeed, comorbidity
and functional and cognitive function can vary substan-
tially amongst older patients, rendering age itself less
relevant as a discriminating prognostic factor. Also in
the risk stratification score of Couchoud et al [15],
comorbidity is much more important for prognosis than
age, which only contributes an additional 1 or 2 points
for those older than 85 or 90 respectively. Nevertheless,
in our current validation cohort, it was clear that age
and comorbidity were linked, with more than half of the
patients older than 85 being in the highest risk stages of
the REIN score. However, vice versa, it also indicates
that a substantial part of the very old does not have
Table 3 Comorbidities in patients in surviving vs dying within
the first 3 months after start of RRT
% in those
who Survived
% in those
who died
Risk estimate
(95 % CI)
Age <75 48.0 27.5 1.41
75–80 17.4 16.7 (1.30–1.56)
80–85 18.6 26.4
85–90 11.7 20.3
>90 4.3 9.1
Gender male 56.6 57.6 0.96
female 43.4 42.4 (0.75–1.23)
Heart Failure Stage 0 52.0 31.1 1.61
Stage 1 14.3 11.2 (1.45–1.80)
Stage 2 16.5 13.8
Stage 3 14.0 23.5
Stage 4 3.3 20.4
Angina Pectoris None 77.7 58.7 1.54
Grade 1 10.4 14.8 (1.35–1.73)
Grade 2 6.4 7.1
Grade 3 4.1 13.8
Grade 4 1.5 5.6
Peripheral
Vascular Disease
None 80.5 68.4 1.26
Claudication 10.9 18.4 (1.08–1.47)
Resting
ischemia
2.4 5.6
Necrosis/
amputation
6.2 7.7
COPD None 78.0 57.7 1.61
Mild 12.6 24.5 (1.37–1.88)
Moderate 7.2 10.7
Severe 2.3 7.1
Myocardial
Infarction
NO 82.5 74.0 1.66
YES 17.5 26.0 (1.19–2.3)
PCI NO 82.3 81.6 1.52
YES 17.7 18.4 (0.72–1.54)
Arrhythmia NO 85.7 78.6 1.64
YES 14.3 21.4 (1.15–2.34)
Diabetes NO 66.1 69.9 0.83
YES 33.9 30.1 (0.61–1.15)
CerebroVascular
Disease
NO 85.4 84.2 1.19
YES 14.6 15.8 (0.90–1.56)
Dementia NO 97.6 95.9 1.75
YES 2.4 4.1 (0.82–3.70)
Table 3 Comorbidities in patients in surviving vs dying within
the first 3 months after start of RRT (Continued)
Liver disease NO 95.1 94.9 1.05
YES 4.9 5.1 (0.54–2.03)
Left ventricular
Hypertrophy
NO 48.8 57.1 0.72
YES 51.2 42.9 (0.54–0.96)
Cancer NO 85.1 76.0 1.80
YES 14.9 24.0 (1.27–2.55)
Nutritional
status
Normal 83.3 53.1 3.06
Malnutrition 14.2 34.7 (2.46–3.85)
Severe
malnutrition
2.5 12.2
Albumin (g/L) <25 10.0 24.0 1.67
25–30 12.1 27.0 (1.48–1.87)
30–35 24.3 21.9
35–40 35.7 19.9
≥40 17.9 7.1
C-reactive
protein (mg/L)
<15 65.6 27.6 2.76
15–60 24.0 39.3 (2.29–3.31)
≥60 10.4 33.2
Renal
Replacement
Therapy
Hospital HD 78.9 87.0 1.78
Satellite HD 9.2 6.2 (1.54–2.1)
PD 11.3 6.9
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comorbidity, and might thus have a good prognosis on
dialysis. Thus, our data confirm that age cannot be the
sole criterion to decide to start or withhold dialysis, though
older age is often associated with more comorbidities.
The use of a risk stratification score can be very help-
ful to better illustrate the odds of a good or bad outcome
in an objective manner. Results of the score and the
associated risk, if presented in a format the patient can
understand, can be of real value in guiding a shared
decision making by creating realistic expectations about
the treatment [18–20]. Our external validation of the
REIN risk stratification score corroborates its use for
such purposes.
Shared decision making comprises 3 stages: informing
the patient, elicit his/her preferences and values, and
assist decision making [21]. The REIN score [15] appears
to be sufficiently accurate to provide the necessary prog-
nostic information to the patient. Care should be taken
however on the way this information is presented to the
patient, as most patients and even physicians struggle in
interpreting relative risks and statistical data [22, 23].
Easy pictographic presentations as presented in Fig. 2
can be helpful to convey the underlying messages of the
data and their implications to the patient. However,
patient’s response to and conclusions drawn from the
presented data might be different, based on their back-
ground beliefs, values and expectations of how their life
(or death) should look like. For an 85 year old, even a
50 % probability of mortality at 3 months might still
justify start of dialysis when an important event, for
example a marriage of a grandchild, is planned in the
near future, whereas for another individual, even a 15 %
mortality probability at 6 months might not suffice to
choose starting or continuing dialysis if the accompany-
ing quality of life is too poor. The elicitation of the
patient’s preferences and values is an important part of
the shared decision making process, and it is important
that the involved professionals avoid mixing up their
own beliefs, values and expectations with those of the
patient and/or his next of kin. A parallel can be drawn
with the area of dialysis withdrawal, where there is
evidence that there is substantial peer pressure amongst
nephrologists on whether or not they believe that with-
drawal of dialysis is ethically defendable [24]. More
important, there is a strong correlation between the
actual occurrence of dialysis withdrawal in a centre and
the beliefs of the treating physician [24]. These observa-
tions underscore the need for easy and neutral picto-
graphic presentation of relative risk, minimizing external
bias and maximizing patient autonomy.
It can be argued that we, as did the original REIN
study, only included patients that actually did start dialy-
sis, and that we therefore do not know the fate of
patients that did not start dialysis. Several studies under-
score however that in patients with one or more comor-
bidities, survival is equal in those who did or did not
start dialysis. Most patients who opt not to start dialysis
most likely have multiple comorbidities, and would thus
end up in the higher risk scores. As such, we believe the
use of a cohort that actually started dialysis does not
Fig. 1 Mortality at 3, 6 and 12 months after start of RRT according to the stages of the abbreviated REIN score
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jeopardize the conclusion of its validity to identify
patients at high risk of poor outcome.
A limitation of our validation might be that the REIN
cohort has similar properties in terms of patient charac-
teristics as the NBVN cohort. In addition, REIN and
NBVN operate in a comparable healthcare environment
in terms of organisation and cultural background. As a
consequence, it can still be that the REIN score does not
discriminate sufficiently well in other healthcare settings
or regions.
The NBVN registry does not capture mobility and
need for assistance for transfer, parameters of functional
capacity. By consequence, we were not able to capture
frailty in our patients. Frailty is a relatively new emerging
concept indicating a lack of physiological reserve. It is
difficult to define in strict terms, but its presence can
easily be assessed from clinical observations. In the
REIN risk stratification tool, it is mainly reflected in the
“mobility” issue, and it contributes substantially to the
overall risk, with 9 points for the maximal score. Differ-
ent geriatric assessment scores for frailty exist, but most
of them are laborious and/or time consuming, and
cannot be performed on a regular or repetitive basis. It
has been demonstrated before that frailty and classical
comorbidity do not always completely overlap [25]. A
simple assessment of the REIN score can discriminate
those patients who might benefit from a more extensive
geriatric assessment by a geriatrician.
It could be argued that the score could be further
improved by adding extra elements. However, it has
been advocated before that the search for a highly accur-
ate score for use in clinical practice is probably not
Fig. 2 Survival according to aREIN stage panel A: 3 month survival; panel B: 12 month survival; Blue dots: patients who survived this period; Red
dots: patients who did not survive this period
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justified [26]. Indeed, patients rather interpret infor-
mation provided by the scores in more general quali-
tative rather than in absolute numerical terms. A
more complex score might be cumbersome and time
consuming to use in clinical practice. Therefore, abso-
lute accuracy should not be strived for, and ease of
use is probably more of importance. One factor that
might improve the score is to include mode of vas-
cular access (catheter vs graft vs fistula), as this has
been demonstrated to be associated with outcome.
However, most likely, there is a high collinearity between
the items already included in the score, and the propensity
to have a catheter as first access.
Conclusions
Our paper provides an external validation of a clinically
applicable risk stratification tool. Such a tool is crucial
to assist evidence based shared decision making on
whether to start dialysis or opt for conservative care.
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